Partners evaluating nanoparticle NanoGlys(TM) as vaccine adjuvant and drug delivery vehicle

/EINPresswire.com/ -- OTTAWA, ONTARIO -- (Marketwired) -- 01/14/16 -- Guelph-based Glysantis Inc. and Canada's "go-to" research and technology organization are investigating the potential of the NanoGlys™ nanoparticle for biomedical applications. The up-and-coming Canadian life science company is taking advantage of the National Research Council of Canada's (NRC) expertise and preclinical models to study how NanoGlys™ could be used as a vaccine adjuvant, drug delivery vehicle, and medical imaging agent.

The first phase of testing will confirm the safety of NanoGlys™, as well as the nanoparticle's ability to reach targeted biological sites and be cleared away thereafter. Future studies will explore if NanoGlys™ can successfully deliver chemotherapeutic agents directly to diseased cells or tissue, and confirm its therapeutic efficacy. The feasibility studies are of strategic importance in determining the most promising applications of the nanoparticle for further development.

Quick Facts

--  Glysantis is a Canadian company specializing in non-toxic, versatile
    nanomaterials. Its leading nanoparticle, NanoGlys™, is a naturally
    occurring, monodisperse organic nanomaterial extracted from plants.

--  NRC's Vaccines Program works with Canadian and international partners to
    develop vaccines against cancer and emerging infections. Our expertise
    in immunomodulation, analytics and bioprocessing enables the Canadian
    vaccine industry to harness advances in adjuvants, biomarkers and
    vaccine production.

Quotes

"The development of new adjuvants and immunomodulators could have a major impact on the efficacy of many vaccines. The National Reseach Council is proud to participate in this innovative project with an up-and-coming Canadian life science company."

Dr. Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada

"The National Research Council's outstanding capabilities and deep expertise in areas of interest to Glysantis are an excellent basis for our preclinical research and development programs. We are excited about this partnership for the development of our technology."

Dr. Thomas Engelhardt, President of Glysantis Inc.

Additional Links

- National Research Council's Vaccines program

- Glysantis

Twitter: @NRC_CNRC

Contacts:
Media Relations Team
National Research Council of Canada
1-855-282-1637 (toll-free, 24/7, in Canada only)
1-613-991-1431 (elsewhere in North America)
media@nrc-cnrc.gc.ca

Dr Thomas Engelhardt, President
Glysantis Inc.
1-919-923-2159
tengelhardt@glysantis.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.